Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al.|The Lancet|2018Cited by 1.3k
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 studyDo‐Youn Oh, Juan W. Valle, Takuji Okusaka et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 245